Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Allegheny General Hospital |
---|---|
Information provided by: | Allegheny General Hospital |
ClinicalTrials.gov Identifier: | NCT00548912 |
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
Condition | Intervention | Phase |
---|---|---|
Kidney Failure, Chronic |
Drug: Spironolactone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
Allegheny General Hospital | |
Pittsburgh, Pennsylvania, United States, 15212 |
Principal Investigator: | Richard Marcus | Allegheny General Hospital |
Study ID Numbers: | RC-3267 |
Study First Received: | October 23, 2007 |
Last Updated: | October 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00548912 |
Health Authority: | United States: Institutional Review Board |
Kidney Failure, Chronic Hemodialysis Spironolactone |
Pathological Conditions, Anatomical Hypertrophy, Left Ventricular Renal Insufficiency Hypertrophy Heart Diseases Urologic Diseases |
Renal Insufficiency, Chronic Kidney Failure, Chronic Kidney Diseases Cardiomegaly Spironolactone Kidney Failure |
Aldosterone Antagonists Natriuretic Agents Therapeutic Uses Hormone Antagonists Physiological Effects of Drugs |
Diuretics Hormones, Hormone Substitutes, and Hormone Antagonists Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |